Synlogic, Inc. (SYBX) Dividend History

Synlogic, Inc. is a clinical-stage biopharmaceutical company focused on developing synthetic biotic medicines—engineered live bacteria designed to treat various diseases. Utilizing proprietary synthetic biology platforms, the company aims to create innovative therapies for conditions such as metabolic disorders, inflammation, and other serious health issues.

Po Box 30, Winchester, MA, 01890
Phone: 617-401-9975
Website:

Dividend History

Synlogic, Inc. currently does not pay dividends

Company News

  • CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the first quarter 2024 and provided a corporate update.

    GlobeNewswire Inc.
  • Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of -54.05% and 2.37%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

    Zacks Investment Research
  • Aadi Bioscience, Inc. (AADI) delivered earnings and revenue surprises of 10.45% and 2.12%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

    Zacks Investment Research
  • Engages Ladenburg Thalmann as financial advisor to assist with previously announced strategic review process Engages Ladenburg Thalmann as financial advisor to assist with previously announced strategic review process

    GlobeNewswire Inc.
  • U.S. stocks traded mostly higher toward the end of trading, with the Nasdaq Composite gaining over 1% on Friday. The Dow traded down 0.09% to 38,691.21 while the NASDAQ rose 1.26% to 15,992.17. The S&P 500 also rose, gaining, 0.55% to 5,025.21. Check This Out: How To Earn $500 A Month From Principal Financial Group Stock Ahead Of Q4 Print   Leading and Lagging Sectors   Information technology shares rose by 1.4% on Friday. In trading on Friday, energy shares fell by 1.2%.   Top Headline   Newell Brands Inc (NASDAQ: NWL) reported upbeat sales for its fourth quarter, but issued a weak forecast. The company reported fourth-quarter revenues of $2.076 billion, beating the analyst consensus of $1.980 billion. Revenues fell 9.1% year over year. Normalized EPS of 22 cents topped the consensus of 17 cents. The company sees FY24 sales decline of 8% to 5%. Newell Brands sees adjusted EPS of 52 cents to 62 cents versus estimates of 77 cents.   Equities Trading UP   Intelligent Bio Solutions ...

    Benzinga
    Featured Companies: INBS NET NWL PLCE
Dividend data last updated 06/07/2025 22:10:04 UTC